When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
LPCN - Lipocine under pressure on extended timeline for FDA review of Tlando application
Lipocine Inc.
The FDA has informed Lipocine (NASDAQ:LPCN) that it needs more time to complete its review of the company's marketing application for oral testosterone replacement therapy Tlando (testosterone undecanoate). The agency's action date was today.
More news on: Lipocine Inc., Healthcare stocks news, Stocks on the move,